Assistant C

Location:

Houston, TX

Posted:

September 03, 2019

Contact this candidate

Resume:

CURRICULUM VITAE

Liang (Leo) Zhang, M.D., Ph.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Assistant Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine,

The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center

1515 Holcombe Boulevard

Unit Number: 429

Houston, TX 77030

Room Number: Faculty Center, FC6.2046

Phone: 713-***-****

Fax: 713-***-****

Email: ********@**********.***

EDUCATION

Degree-Granting Education

MD, The Fourth Military Medical University, Xi’an, China. 1992, Medicine

MS, The Fourth Military Medical University, Xi’an, China. 1998, Dermatological Molecular Immunology and Cell Biology

PhD, The Fourth Military Medical University, Xi’an, China. 2001, Dermatological Molecular Immunology and Cell Biology

Postgraduate Training

Research Fellow, Lindsley F. Kimball Research Institute, New York Blood Center, NY, 12/2004-6/2005

Postdoctoral Fellow of Tumor Immunology and Cell Biology, Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, 7/2005-7/2010

EXPERIENCE/SERVICE

Academic Appointments

Chief Resident, Department of Dermatology, Xijing Teaching Hospital, Fourth Military Medical University, Xi’an, China, 7/1998-7/1999

Instructor, Attending Physician, Center of Clinical Oncology, Xijing Teaching Hospital, Xi’an, China, 7/2001-7/2004

Visiting Scientist, Department of Molecular Pathology University of Texas, M.D. Anderson Cancer Center, Houston, TX, 7/2004-11/2004

Instructor, Department of Lymphoma & Myeloma, University of Texas, M.D. Anderson Cancer Center, Houston, TX, 7/2010-5/2013

Assistant Professor, Department of Lymphoma & Myeloma, University of Texas, M.D. Anderson Cancer Center, Houston, TX, 6/2013-present

Administrative Appointments/Responsibilities

N/A

Other Appointments/Responsibilities

N/A

Endowed Positions

N/A

Consultantships

N/A

Military or Other Governmental Service

N/A

Institutional Committee Activities

N/A

HONORS AND AWARDS

Young Investigator Award, American Journal of Hematology, 2009

RESEARCH

Grants and Contracts

Funded

Flagship Project 1 Co-PI, B-cell Lymphoma Moonshot Grant. Targeted therapies in mantle cell lymphoma, 9/1/2014-present ($500,000/year)

Co-Investigator, FoxM1 as a novel therapeutic target to overcome ibrutinib resistance in mantle cell lymphoma. NIH grant R21, #CA234851, 12/05/2018-11/30/2020 ($208,800)

Co-Investigator, BET Protein Antagonist-Based Targeted Therapy of Mantle Cell Lymphoma

NIH R01 CA210250, 7/1/2017-6/30/2022 ($390,143/year)

Co-Investigator, An Adaptive Personalized Clinical Trial using a Patient-Derived Xenograft Strategy to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma, Cancer Prevention & Research Institute of Texas (CPRIT), RP160019, 3/1/2016-2/28/2019 ($799,527)

Pending

N/A

Other

N/A

Completed

Co-Investigator, Overcoming Primary Ibrutinib Resistance in Mantle Cell Lymphoma Using Patient-Derived Models and Molecular Profiling, NIH R21, CA202104, 7/1/2016-6/30/2018 ($268,664)

Co-Investigator, Mechanisms of Resistance to Ibrutinib in Mantle Cell Lymphoma, Pharmacyclics, 9/1/2014-08/31/2017 ($500,000)

Co-Investigator, Institutional Research Grant (IRG). A study of the action of a novel potent topoisomerase II inhibitor berubicin on mantle cell lymphoma in MCL-bearing SCID-hu mouse model, 4/1/2011-4/1/2014 ($50,000)

Co-Investigator, NIH-SPORE DRP. The effect of BTK inhibitor PCI-32765 plus carfilzomib on tumor survival, propagation, metastasis, and microenvironment in patient-derived MCL-bearing SCID-hu mice, 6/1/2012-6/1/2013 ($25,000)

Co-Investigator, Onyx Research Fund. Carfilzomib, a novel proteasome inhibitor, induces growth inhibition and apoptosis of mantle cell lymphoma in patient-derived MCL-bearing SCID-hu mice, 3/1/2012-3/1/2014 ($50,000)

Co-Investigator, Sister Institution Network Fund (SINF). A Phase II, Multicenter, International Study of Lenalidomide and Rituximab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Non-Hodgkin Lymphoma, Transformed Large Cell Lymphoma, and Grade 3 Follicular Lymphoma, 3/1/2012-3/1/2014 ($100,000)

Co-Investigator, Onyx Research Fund. Synergistically antitumor effect of carfilzomib with BTK inhibitor PCI-32765 on mantle cell lymphoma, 3/1/2014-3/2016 ($50,000)

Not Funded

N/A

Protocols

Funded

Principal Investigator, The Actions of Novel Anti-Tumor Agents In Vivo. ACUF ID # 00001260. 01/31/2012- present

Principal Investigator, Collection and use of samples from patients with lymphoma, multiple myeloma, and other plasma cell dyscrasias for translational research. Protocol# LAB11-0342, 2011-present

Principal Investigator, The effect of novel agents and their combination in B-cell hematological malignancies and multiple myeloma in vitro and in vivo. Protocol# PA11-0986, 2011-present

Principal Investigator, The effect of Bruton’s tyrosine kinase (BTK) inhibitor, PCI-32765, in lymphoma and multiple myeloma in vitro and in vivo. Protocol# PA11-0988, 2011-present

Co-Principal Investigator, The effect of berubicin on multiple myeloma in vitro and in vivo. Approved, 2012-2015, LAB11-0108

Co-Principal Investigator, The effect of berubicin on mantle cell lymphoma cells in vitro and in vivo. Approved, 2012-2015, LAB11-0110.

Unfunded

N/A

Patents and Technology Licenses

Patents

Molecular Signature for Selecting Lymphoma Patients for Treatment with Ibrutinib or IACS-010759 – Patent No. 62/819,937

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

N/A

PUBLICATIONS

Peer-Reviewed Original Research Articles (* co-first author, # corresponding author)

1.Zhu F, Guo H, Bates PD, Zhang S, Zhang H, Nomie KJ, Li Y, Lu L, Seibold KR, Wang F, Rumball I, Cameron H, Hoang NM, Yang DT, Xu W, Zhang L, Wang M, Capitini CM, Rui L. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia. 2019 May 23. doi: 10.1038/s41375-019-0489-6. PMID: 31123343

2.Zhang L*, Yao Y*, Zhang S*, Liu Y*, Guo H, Ahmed M, Bell T, Zhang H, Han G, Kovacs J, Pham L, Sun Y, Francesco E, Feng N, Mao X, Song X, Zhang J, Marszalek J, Heffernan T, Draetta G, Jones P, Futreal A, Nomie K, Wang L and Wang M. Metabolic reprogramming towards OXPHOS identifies a novel therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019 May 8;11(491). pii: eaau1167. doi: 10.1126/scitranslmed.aau1167. PMID:31068440

3.Lee J*, Zhang L*, Sukhanov M, Venkataraman G, Alikhan M, Lu P, Guo A, Galanina N, Chiosis G, Wang M and Wang L. Activation of MYC, a bona fide client of HSP90, underlies intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv 2(16):2039-2051, 2018. PMID:30115641

4.Pham L#, Huang S, Zhang J, Bell T, Zhang H, Zhou S, Lam L, Wang J, Westin J, Davis E, Young K, Medeiros J, Ford, J, Nomie K, Zhang L# and Wang M#. Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas. Clin Cancer Res 24(16):3967-3980, 2018. PMID: 29666304

5.Guo H, Liu Y, Zeng D, Huang S, Bell T, Li C, Zhang H, Lorence E, Ye H, Gong T, Lam L, Desai AP, Ahmed M, Nomie K, Jiang C, Zhang L and Wang M. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene 2018 Oct 25. doi: 10.1038/s41388-018-0550-3. PMID: 30361685

6.Li C, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M. Pleiotropic action of novel bruton's tyrosine kinase inhibitor bgb-3111 in mantle cell lymphoma. Mol Cancer Ther 2018 Nov 9. pii: molcanther.0478.2018. doi: 10.1158/1535-7163. PMID:30413649

7.Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, Yao Y, Zeng D, Ahmed M, Nomie K, Zhang L and Wang M. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 2018 Mar 20;8(3):33. doi: 10.1038/s41408-018-0066-7. PMID: 29559616

8.Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578-587, 2018. PMID: 30175400

9.Jain P, Romaguera J, Srour SA, Lee HJ, Hagemeister F, Westin J, Fayad L, Samaniego F, Badillo M, Zhang L, Nastoupil L, Kanagal-Shamanna R, Fowler N, Wang ML. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018 May 22. doi: 10.1111/bjh.15411. PMID: 29785709

10.Li Y, Wang F, Lu L, Zhu F, Huang S, Nomie K, Zhang L, Yang DT, Huang W, Kahl BS, Safe S, Wang M, Rui L. NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. Blood Cancer J. 2017 Nov 23;7(12):632. doi: 10.1038/s41408-017-0005-z. PMID: 29167454

11.Zhang L, Nomie K, Zhang H, Bell T, Pham LV, Kadri S, Segal J, Li S, Zhou S, Santos D, Richard S, Sharma S, Chen W, Oriabure O, Liu Y, Huang S, Guo H, Chen Z, Tao W, Li C, Wang J, Fang B, Wang J, Li L, Badillo M, Ahmed M, Thirumurthi S, Huang SY, Shao Y, Lam L, Yi Q, Wang L, Wang M. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin Cancer Res. 23(15):4212-4223, 2017. PMID: 28348046

12.Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Li J, Jiang H, Meads M, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Moscinski L, Koomen J, Dalton W, Shain K, Wang M, Sotomayor E, and Tao J. Unification of De Novo and Acquired Ibrutinib Resistance in Mantle Cell Lymphoma (MCL). Nature Communications. Nat Commun 2017 Apr 18; 8:14920. doi: 10.1038/ncomms14920.

13.Liu Y, Yin Y, Zhang Z, Li C, Zhang H; Zhang D, Jiang C, Nomie K, Zhang L, Wang M, and Zhao G. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. European Journal of Medicinal Chemistry. Eur J Med Chem. 2017 Sep 29;138:543-551. doi: 10.1016/j.ejmech.2017.06.067. Epub 2017 Jun 30. PMID: 28704757

14.Liu Y, Yin Y, Zhang J, Nomie K, Zhang L, Yang D, Wang ML, Zhao G. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d] pyrimidine Derivatives as Akt Inhibitors. Arch Pharm (Weinheim) 349(5):356-62, 5/2016. e-Pub 3/2016. PMID: 26991997.

15.Lee HJ, Romaguera JE, Feng L, Desai AP, Zhang L, Fanale M, Samaniego F, Hagemeister FB, Fayad LE, Rodriguez MA, Medeiros JL, Hartig K, Nomie K, Ahmed M, Badillo M, Ye H, Oki Y, Lin P, Nastoupil L, Westin J, Wang M. Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. Oncologist. 2017 May;22(5):549-553. doi: 10.1634/theoncologist.2016-0328. Epub 2017 Apr 13. PMID: 28408615

16.Weng J, Moriarty KE, Baio FE, Chu F, Kim SD, He J, Jie Z, Xie X, Ma W, Qian J, Zhang L, Yang J, Yi Q, Neelapu SS, Kwak LW. IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. Oncoimmunology. 2016 Oct 7;5(12):e1237327. doi: 10.1080/2162402X.2016.1237327. eCollection 2016. PMID: 28123872

17.Ahmed M, Zhang L, Nomie K, Lam L, Wang M. Gene mutations and actionable genetic lesions in mantle cell lymphoma. Oncotarget. 2016 Sep 6;7(36):586**-*****. doi: 10.18632/oncotarget.10716. PMID: 27449094

18.Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, Rosa MD, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 2016 PMID: 26640039.

19.Zhang L, Bi E, Hong S, Qian J, Zheng C, Wang M, Yi Q. CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma. Oncotarget 6(34):36032-40, 2015. PMID: 26447613.

20.Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood 126(13):1565-74, 2015. PMCID: PMC4582333.

21.Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 126(6):739-45, 2015. PMCID: PMC4528064.

22.Gao W, Wang M, Wang L, Lu H, Wu S, Dai B, Ou Z, Zhang L, Heymach J, Gold K, Minna J, Roth J, Hofstetter W, Swisher S, Fang F. Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non–Small Cell Lung Cancer Cells. JNCI 106(9): 1-4, 2014 PMID:25214559

23.Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, Huang H, Lin T, Romaguera J, Wang M. Clinical Outcomes of a Novel Combination of Lenalidomide and Rituximab Followed by Stem Cell Transplantation for Relapsed/refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Oncotarget 5(17):7368-80, 2014 PMID: 25228589

24.Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014;7(1):41. doi: 10.1186/175*-****-*-**. PMID:24886772

25.Pham LV, Vang MT, Tamayo AT, Lu G, Challagundla P, Jorgensen JL, Rollo AA, Ou Z, Zhang L, Wang M, Ford RJ. Involvement of tumor-associated macrophage activation in vitro during development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease. Leuk Lymphoma 56(1):186-93, 1/2015. e-Pub 4/2014. PMID: 24611650.

26.Axelrod M, Ou Z, Brett K, Zhang L, Lopez E, Tamayo A, Gordon V, Ford R, Williams M, Pham L, Weber M, Wang M. Combinatorial drug screening identifies synergistic co-targeting of Bruton’s Tyrosine Kinase and the proteasome in mantle cell lymphoma. Leukemia 28(2):407-10, 2014 PMID: 23979520

27.Zhang L*, Pham L*, Newberry K, Qian J, Sun L, You Y, Yang J, Ou Z, Lin X, Ford R, Zhao X, Kwak L, Yi Q, Wang M. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther 12(11): 2494-2504, 2013 PMID: 23990113

28.Wang M, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JF, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry KJ, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang B, Beaupre DM, Kunkel LA, Blum KA. Targeting Bruton’s Tyrosine Kinase with Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. N Engl J Med 369(6):507-16, 2013 PMID: 23782157

29.Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu S, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry K, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young K, Champlin R, Kwak L, Fayad L. Oral Lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular, and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 2013 PMID: 23545991

30.Zhang K, Wang M, Tamayo A, Shacham S, Kauffman M, Lee J, Zhang L, Li C, Ford R, Pham L. Novel Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists for Therapy in Mantle Cell Lymphoma. Exp Hematol 41(1):67-78,2013

31.Zhang L, Yang J, Qian J, Li H, Romaguera R, Kwak L, Wang M, Yi Q. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120(18):3783-92, 2012.

32.Sun L*, Zhang L*, Qian J, Yang J, Yi Q, Dong W, Wang M. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res 36(3):363-8, 2012.

33.Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 2012.

34.Wang M, Luis Fayad L, Wagner-Bartak N, Zhang L, Hagemeister, F, Neelapu S, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young K, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab in patients with relapsed and refractory mantle cell lymphoma: a phase I/II clinical trial. Lancet Oncol 13(7):716-23, 2012.

35.Qian Z*, Zhang L*, Cai Z, Sun L, Wang H, Yi Q, Wang M. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 35:385-6, 2010.

36.Qian J, Hong S, Wang S, Zhang L, Sun L, Wang M, Yang J, Kwak LW, Hou J, Yi Q. Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood 114(18):3880-89, 2009.

37.Zhang L Qian Z*, Cai Z, Sun L, Wang H, Bartlett JB, Yi Q, Wang M. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 84(9):553-9, 2009.

38.Wang M*, Zhang L*, Han X, Yang J, Qian J, Hong S, Lin P, Shi Y, Romaguera J, Kwak LW, Yi Q. A Severe Combined Immunodeficient -hu In vivo Mouse Model of Human Primary Mantle Cell Lymphoma. Clin Cancer Res 14(7): 2154-60, 2008.

39.Wang M*, Han X*, Zhang L*, Yang J, Qian J, Shi Y, Kwak L, Romaguera J, Yi Q. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 22: 179–185, 2008.

40.Wang M*, Zhang L*, Han X*, Yang J, Qian J, Hong S, Samaniego F, Romaguera J, Yi Q. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 109(12):5455-62, 2007.

41.Qian J, Xie J, Hong S, Yang J, Zhang L, Han X, Wang M, Zhan F, Shaughnessy JD, Epstein J, Kwak LW, Yi Q. DKK1 is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110(5):1587-94, 2007.

42.Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti- 2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8):3028-35, 2007.

43.Jin B, Ren J, Zhang L, Wang H, Bai J, Zhang L, Si X. The research for mtDNA D-loop gene mutation in plasma of primary breast cancer patients. Chinese Clinical Oncology, 2005; 10(1) :1-3

44.Wang H, Ren J, Zhang L. CDH1 germline mutation in hereditary gastric carcinoma. World J Gastroenterol. 2004;10(21):3088-93.

45.Zhang H, Ren J, Zhang L, Zhang L, Zhang y, Si X, Fan L, Pan B. In vitro Induction dendritic cells from mobilized peripheral blood stem cells and their function identification. J Fourth Mil Med Univ, 2003; 24:83-5

46.Li Z, Xu Z, Zhang L, Liu K. The molecular epidemiological study of HIV-1 in Shaanxi province. Chin J of Dermatol & Venerol, 2003; 17(1): 12-15

47.Zhang L, Ren J, Zhang L, Zhang H, Jin B, Pan B, Si X, Zhang Y, Wang Z, Pan Y. Construction and expression of recombined human AFP eukaryoyic expression vector. World J Gastroenterol, 2003; 9(7): 1465-1468

48.Jin B, Ren J, Zhang L, Wang H, Bai J, Zhang Y, Si X, Pan B. Detection of Mit D-loop HVR2 mutation of plasma in the patients with breast cancer with HPLC technique. J Fourth Mil Med Univ, 2002; 24:911-3

49.Zhang L, Liu Y, Yang Q, Li W, Li C, Li Z, Ren J, Zhang Y. Study on the epitope mapping which bind to polyclonal anti-keratin autoantibodies using a phage random peptide library. Chin J Dermatol, 2002; 35(2): 137-9

50.Lui S, Wang H, Si X, Zhang Y, Zhang L, Pan B, Ren J. The significance of P53 gene mutation of plasma cycle nucleotides in breast cancer. J Fourth Mil Med Univ, 2002; 23:835-7

51.Zhang L, Liu Y, Yang Q, Ren J, Li Z. Screening the mimetic oligopeptide of keratin 14 and 17 related with psoriasis from phage random peptide library”. J Fourth Mil Med Univ, 2001; 22(24): 2244-9

52.Yang Q, Ma W, Li S, Li Z, Zhang L, Ren J. Expression and immunogenicity of the eukaryotic vector of mimotope mgc derived from glycoprotein C of herpes simplex virus. J Cell Mol Immunol, 2001; 17(5): 422-5

53.Li Z, Xu Z, Xing A, Yang Q, Ren J, Zhang L. First case was reported in China that a man who had sexual relation without any protection methods with his HIV infected wife during a long period of time was not infected by HIV. J fourth Mil Med Univ, 2001; 22(16): 1522-4

54.Zhang L, Zhao X, Lan F, Liu Y, Liu Y. Effect of the anti-keratin monoclonal antibody 5G5 on the cultured keratinocytes proliferation. Chin J Dermatol, 2001; 34(4): 274-6.

55.Lan F, Zhang L, Zhao X, Liu Y, Chen S. Generation and characterization of a panel of keratins from the cultured human keratinocytes in vitro. J Fourth Mil Med Univ, 1999; 20(1): 78-9

56.Zhang L, Liu Y, Liu Y, Zhang S. Generation and characterization of a series of monoclonal antibodies against keratins. J Cell Mol Immunol, 1999; 15(1): 58-59

Invited Articles

1.Wang Y, Zhang L, Champlin RE, Wang ML. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 97:455–468, 2015. PMID: 25669675.

2.Desai M, Newberry K, Ou Z, Wang M, Zhang L. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol 5(3):91-101, 2014

3.Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol 93(4):541-56, 2014

4.Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma : current data on safety and efficacy. J Hematol Oncol. 2013 Aug 2; 6:55. doi: 10.1186/175*-****-*-**.

5.Zhou Y, Zhang L, Romaguera J, Delasalle K, Han X, Du X, Kwak L, Yi Q, Wang M. Immunotherapy in mantle cell lymphoma: Anti-CD20-based therapy and beyond. Am J Hematol 83(2):144-9, 2008.

6.Wang M, Zhou Y, Zhang L, Nguyen CA, Romaguera J. Use of bortezomib in B-cell non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther 6(7): 983-91, 2006.

Editorials

1.Zhang L, Newberry K, Wang M. Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. Expert Review of Clinical Immunology 9(6):495-7, 2013